Skip to main content

HubXchange

HubXChange logo

Antibody Therapeutics Xchange - San Francisco - 2025

Page Banner 1

  1. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Selecting efficacious and safe cytotoxic combinations for dual payloads
    What causes resistance to ADCs with standard-of-care payloads in patients? How should we choose betw ...
    Amandeep Gakhal
    Amandeep Gakhal, Senior Director - ADC & Cell Biology, Late Discovery - Hexagon Bio
  2. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Crafting the optimal linker: Leveraging insights from the past to innovate for target-specificity, format-compatibility, indication alignment, and payload efficacy - Topic TBC
    Sachin Shivatare
    Sachin Shivatare, Scientific Lead- Antibody-Drug Conjugates, Oncology - Eli Lilly
  3. AI & Machine Learning
    • AI & Machine Learning
    Towards de novo discovery of antigen-specific antibodies using AI and experimental feedback
    Why does sequence-to-function prediction remain noisy and context-dependent? Why do naïve repertoire ...
    Eswar Iyer
    Eswar Iyer, CEO & Co-Founder - Aikium
  4. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Poster Presentation: Development of Dual-Payload Antibody Drug Conjugates
  5. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Poster Presentation: Optimizing Linker Design for ADCs: CRO Expertise in Stability, Selectivity, and Payload Release
  6. AI & Machine Learning
    • AI & Machine Learning
    Poster Presentation:
  7. Formats & Scaffolds
    • Formats & Scaffolds
    Careful selection of building block properties and compatibility essential to boost overall success of multispecifics
    Rishi Bedi
    Rishi Bedi, CEO - Y-Trap
  8. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Tackling the challenge of enhancing cytotoxic payload potency while reducing off-target toxicity in ADCs
  9. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Balancing linker stability to ensure controlled payload release without compromising ADC efficacy
  10. AI & Machine Learning
    • AI & Machine Learning
    Unsupervised clustering of B-cell receptor sequences to identify novel germline families in early-stage antibody discovery
  11. Formats & Scaffolds
    • Formats & Scaffolds
    Addressing engineering challenges with bispecific and immunocytokine drugs
  12. ADC Cytotoxic Payload
    • ADC Cytotoxic Payload
    Reducing resistance of cancer cells to payloads
    Resistance mechanisms to ADCs include drug exports and target mutations. What are we missing? Approv ...
    Remi-Martin Laberge
    Remi-Martin Laberge, Co-founder, CTO - Arda Therapeutics
  13. ADC Linker Design & Conjugation Technologies
    • ADC Linker Design & Conjugation Technologies
    Product development studies for optimization of ADC payload release
    How can we balance payload release with drug product (DP) stability?  What is the bystander effect, ...
    Rosario Mollo
    Rosario Mollo, Senior Director, CMC - Rubedo Life Sciences
  14. AI & Machine Learning
    • AI & Machine Learning
    Addressing an important challenge faced: AI/ML assisted antibody engineering - revolution or hype?
    How can AI/ML models effectively integrate the intricate relationships between protein sequence, str ...
    Sayantan Mitra
    Sayantan Mitra, Head of Protein Sciences - BigHat Biosciences
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Spotlight Presentation:
  16. Bi/Multispecifics
    • Bi/Multispecifics
    Technologies accelerating engineering into advanced modalities
  17. Lead Identification & Optimization
    • Lead Identification & Optimization
    Advancing biologics discovery and building better medicines
  18. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Target selection to avoid off-target effect and cross-reactivity with healthy tissues
    Is there a need for novel targets that can differentiate based on biology and overcome target-depend ...
    Venita DeAlmeida
    Venita DeAlmeida, Vice President, Program Development - ALX Oncology
  19. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Poster Presentation: Lead Identification & Optimization topic: Integration of Rabbit Antibody Discovery with LENSai as a Comprehensive Solution for Therapeutics Generation
  20. Formats & Scaffolds
    • Formats & Scaffolds
    Poster Presentation:
  21. Bi/Multispecifics
    • Bi/Multispecifics
    Poster Presentation: Solving the Bispecific Antibody Mispairing Challenge in Preclinical R&D
    Efficient bispecific antibody (bsAb) production requires precise assembly of multiple chains. Combin ...
    Dylan Brethour
    Dylan Brethour, Senior Account Manager - Evitria
  22. Lead Identification & Optimization
    • Lead Identification & Optimization
    Poster Presentation:
  23. Formats & Scaffolds
    • Formats & Scaffolds
    Challenges of using single domain antibodies as new modalities of multifunctional biologics
    How can cost and efficiency be balanced in the discovery of optimal SDAbs for use in multifunctional ...
    Andrew Peterson
    Andrew Peterson, Director - Akiiwan Therapeutics
  24. Bi/Multispecifics
    • Bi/Multispecifics
    Bi/Multispecific antibodies: challenges in translation [Topic TBC]
    Mohan Srinivasan
    Mohan Srinivasan, Associate Vice President Biologics, Oncology - Eli Lilly and Company
  25. Lead Identification & Optimization
    • Lead Identification & Optimization
    Addressing an important challenge faced: Balancing speed and quality in antibody lead identification: Can emerging technologies deliver both?
    Can large-scale screening platforms capture functional and developability complexity, or are we miss ...
    Starlynn Clarke
    Starlynn Clarke, Director, Preclinical Biology - Rondo Therapeutics
  26. Target Selection & Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Enhancing antigen-specific binding affinity for improved clinical efficacy
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Spotlight Presentation:
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Drinks-Canape Reception
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Afternoon Refreshments
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Networking Lunch
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Morning Refreshments
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    1-2-1 Meetings / Networking Break
  36. Bi/Multispecifics
    • Bi/Multispecifics
    Advances and challenges in developing multispecific antibodies
    What are the novel mechanisms of action? Is there an optimal format? What are the challenges in deve ...
    William Sun
    William Sun, Director - Vaxart
  37. Lead Identification & Optimization
    • Lead Identification & Optimization
    Leveraging AI and early structural insights to power rational antibody lead design and optimization
  38. Target Selection and Mechanisms of Action
    • Target Selection & Mechanisms of Action
    Overcoming membrane protein complexes using display technologies [Topic TBC]
    Danielle Dettling
    Danielle Dettling, CSO and Co-Founder - Fury Biosciences, LLC
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Opening Address & Keynote Presentation:
    • Bi/Multispecifics
    • Formats & Scaffolds
    • Target Selection & Mechanisms of Action
    • AI & Machine Learning
    • ADC Linker Design & Conjugation Technologies
    • ADC Cytotoxic Payload
    • Lead Identification & Optimization
    Registration
Search